Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Square Rival iZettle Raises $67M From Intel and Zouk
54:32 - Today’s "BWest Byte" is $67 million, for how much iZettle, a Swedish payments startup and rival to Jack Dorsey's Square, has raised from Intel and Zouk. Bloomberg's Matt Miller reports on "Bloomberg West." (Source: Bloomberg)
  • What's Next for Flexible Electronic Technology?
  • Facebook Cracks Down on Video Pirates
  • Deep Dive: Is Market Turmoil Hurting Consumer Sentiment?